Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | USP2 | O75604 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.50 |
| ▸ | RELA | Q04206 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4999755 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1USP2CYP1A2CYP2D6 | |
| SCHEMBL8199831 | 0.93 | NPC1 (0.56) | SMN1; SMN2ALDH1A1USP2CYP1A2CYP2D6 | |
| SCHEMBL14074104 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1USP2CYP1A2CYP2D6 | |
| SCHEMBL8199175 | 0.85 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1USP2CYP1A2CYP2D6 | |
| SCHEMBL3879023 | 0.83 | NPC1 (0.52) | SMN1; SMN2ALDH1A1USP2CYP1A2CYP2D6 | |
| SCHEMBL313138 | 0.83 | NPC1 (0.52) | SMN1; SMN2ALDH1A1USP2CYP1A2CYP2D6 | |
| SCHEMBL21348466 | 0.79 | SMN1; SMN2 (0.73) | SMN1; SMN2ALDH1A1USP2CYP1A2CYP2D6 | |
| SCHEMBL21695725 | 0.79 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1USP2CYP1A2CYP2C19 | |
| SCHEMBL8267163 | 0.77 | SMN1; SMN2 (0.88) | SMN1; SMN2ALDH1A1USP2TP53RAB9A | |
| SCHEMBL8266868 | 0.77 | RAB9A (0.77) | SMN1; SMN2ALDH1A1USP2CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349831-B2 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349831-B2 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | disclosed |
| WO-2008057282-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221101-A1 | Calcium receptor modulating agents | CASR, RYR1, RYR2 | SMN1; SMN2 2433/4885ALDH1A1 3089/4885USP2 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.